16th International AIDS Conference Toronto, Canada - August 13 - 18, 2006

MICRONUTRIENT SUPPLEMENTATION INCREASES CD4 COUNT IN HIV-INFECTED INDIVIDUALS ON HAART: A PROSPECTIVE, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL

Int Conf AIDS. 2006 Aug 13-18;16 Abstract No. MoAb0402

Kaiser J.¹, Baum M.², Campa A.², Ondercin J.³, Leoung G.⁴, Pless R.^5
1University of California at San Francisco Medical School, Medicine, San Francisco, United States, ²Florida International University, Nutrition, Miami, United States, ³The Jonathan Lax Treatment Center, Philadelphia, United States, ⁴Saint Francis Memorial Hospital, HIV Care, San Francisco, United States, ⁵Ovation Research Group, Highland Park, United States

BACKGROUND: This is a prospective, randomized, double-blinded, placebo-controlled trial designed to examine the immunologic, metabolic, and clinical effects of a micronutrient supplement in HIV-infected patients currently taking highly active antiretroviral therapy (HAART).

METHODS: Forty HIV-infected patients taking a stavudine and/or didanosine-based HAART regimen were prospectively randomized to receive micronutrients or placebo twice daily for 12-weeks. Data was collected at 4-week intervals including immunologic, metabolic, and clinical measurements. Endpoints included measuring the micronutrient´s effect on several immunologic, metabolic, and clinical parameters, as well as on the symptom of distal symmetrical polyneuropathy (DSP).

RESULTS: The mean absolute CD4 count rose by an average of 65 cells in the micronutrient group versus a 6 cell decline in the placebo group at 12-weeks (P=0.029 ITT). The absolute CD4 count rose by an average of 24% in the micronutrient group versus a 0% change in the placebo group (P=0.01 ITT). Peripheral neuropathy symptoms also declined to a greater extent in the micronutrient than placebo groups though this difference was not statistically significant at 12-weeks. Fasting serum glucose, insulin, and lipids were not adversely affected in the patients taking the micronutrients.

[Mean Change in CD4 Cells]

CONCLUSIONS: Micronutrient supplementation can significantly improve CD4 cell count reconstitution in HIV-infected patients taking HAART. The micronutrient supplement tested was well-tolerated and may hold promise as an adjuvant therapy in the treatment of HIV. Further investigation is warranted.

Download PDF of this abstract.

2006-08-13
MoAb0402

Copyright © 2006 - International AIDS Society (IAS). All information and content relating to the abstracts from the 16th International AIDS Conference, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is a 501c(3) not-for-profit organization made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, GlaxoSmithKline, the National Library of Medicine, Roche / Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.